C-Reactive Protein,Interleukin 6,and N-Terminal Pro-Brain Natriuretic Peptide Following Cardioversion of Atrial Fibrillation: Is There a Role of Biomarkers in Arrhythmia Recurrence?
Restricted accessOtherFirst published online May, 2011
C-Reactive Protein,Interleukin 6,and N-Terminal Pro-Brain Natriuretic Peptide Following Cardioversion of Atrial Fibrillation: Is There a Role of Biomarkers in Arrhythmia Recurrence?
Aims: We investigated the role of high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), and N-terminal pro-brain natriuretic peptide (NTpro-BNP), in atrial fibrillation (AF) recurrence rate. Methods: A total of 80 patients with first AF episode were studied prospectively. Echocardiography (ECG), Holter ECG, and measurements of hsCRP, IL-6, and NTproBNP were performed immediately post conversion and at 1 month. Results: Recurrence was positively related to left atrial volume (P < .001), with no difference in NTpro-BNP, hsCRP, and IL-6. Decreased NTpro-BNP was observed in all at 1 month (P < .001, F = 63.4) and was positively related to left atrial volume (P < .01). In the lone AF subgroup, NTpro-BNP was lower and dropped significantly at 1 month (interaction F = 6.53, P < .01). Conclusions: Atrial volume was related to AF recurrence, whereas hsCRP, IL-6, and NTpro-BNP were not reliable for AF relapse. Relation of NTpro-BNP to left atrial volume could indicate a role in the atrial remodeling process.
Li H., Riedel R., Oldmeyer JB, Rovang K., Hee T.Comparison of recurrence rates after direct-current cardioversion for new-onset atrial fibrillation in patients receiving versus those not receiving rhythm-control drug therapy. Am J Cardiol. 2004;93(1):45-48.
2.
Van Noord T. , Tieleman RG, Bosker HA, et al. Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace. 2004;6(4):343-350.
3.
Singh NB, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.
4.
Engelmann MDM , Svendsen HJInflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005; 26(20):2083-2092.
5.
Chung MK, Martin DO, Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001; 104(24):2886-2891.
6.
Aviles RJ, Martin DO, Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108(24): 3006-3010.
7.
Psychari SN, Apostolou TS, Sinos L., Hamodraka E., Liakos G., Kremastinos DTRelation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation . Am J Cardiol. 2005;95(6): 764-767.
8.
Casaclang-Verzosa G., Gersh BL, Tsang TSStructural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation . J Am Coll Cardiol. 2008; 51(1):1-11.
9.
Ellinor PT, Low AF, Patton KK, Shea MA, MacRae CADiscordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol. 2005;45(1):82-86.
10.
Buob A., Jung J., Siaplaouras S., Neuberger HR, Mewis C.Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol. 2006;29(6):559-563.
11.
Fuster V., Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006 ;48:854-906.
12.
Lang RM, Bierig M., Devereux RB, et al. Recommendations for chamber quantification: a report of the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 ;18(12):1440-1463.
13.
Goetze JP, Friis-Hansen L., Rehfeld JF, Nilsson B., Svendsen JHAtrial secretion of B-type natriuretic peptide. Eur Heart J. 2006; 27(14):1648-1650.
14.
Levin ER, Gardner DG, Samson WKNatriuretic peptides. N Engl J Med.1998;339(5):321-328.
15.
Kundsen CW, Omland T., Clopton P., et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005;46(5): 838-844.
16.
Inoue SI, Murakami Y., Sano K., Katoh H., Shimada T.Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail. 2000;6(2):92-96.
17.
Wozakowska-Kaplon B.Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol. 2004;93(12):1555-1558.
18.
Date T., Yamane T., Inada K., et al. Plasma brain natriuretic peptide concentrations in patients undergoing pulmonary vein isolation. Heart. 2006;92(11):1623-1627.
19.
Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation. 2004; 110(2):124-127.
20.
Watanabe E. , Arakawa T., Uchiyama T., Kodama I., Hishida H. High- sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after cardioversion. Int J Cardiol. 2006;108(3):346-353.
21.
Dernellis J. , Panaretou M.Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J.2004;25(13):1100-1107.
22.
Conway DS, Buggins P., Hughes E., Lip GYPredictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol . 2004;94(4):508-510.
23.
Malouf JE, Kanagala R., Al Atawi FO, et al. High sensitivity C-reactive protein. A novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol. 2005;46(7):1284-1287.
24.
Leftheriotis DI, Fountoulaki KT, Flevari PG, et al. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol.2009 ;135(3):361-369.
25.
Wazni O., Martin DO, Marrouche NF, et al. C-reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart. 2005 ;91(10):1303-1305.
26.
Loricchio ML , Cianfrocca C., Pascheri V., et al. Relation of C-reactive protein to long- term risk of recurrence of atrial fibrillation after electrical cardioversion . Am J Cardiol. 2007;99(10): 1421-1424.
27.
Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R., Lie KIPrediction of uneventful cardioversion and maintenance of sinus rhythm from direct- current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 1991; 68(1):41-46.
28.
Tveit A., Seljeflot I., Grundvolt I., Abdelnoor M., Smith P., Arnesen H.Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007;99(11):1544-1548.
29.
Letsas KP, Weber R., Bürke G., et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace.2009;11(2): 158-163.
30.
Kourliouros A., Camm AJDoes inflammation influence atrial fibrillation recurrence following catheter ablation? Europace. 2009;11(2):135-137.
31.
Ma KK, Ogawa T., de Bold AJSelective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by the pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol. 2004;36(4):505-513.
32.
Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 ;347(32):1825-1833.
